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Abstract  63 
Background: Surgical site infections are common, occurring in up to 25% of >4 million 64 
operations performed in England each year. Previous trials of the effect of wound dressings 65 
on the risk of developing a surgical site infection are of poor quality and underpowered.  66 
Methods and design: This study is a feasibility and pilot trial to examine the feasibility of a 67 
full trial that will compare simple dressings, no dressing and tissue-glue as a dressing. It is 68 
examining the overall acceptability of trial participation, identify opportunities for refinement, 69 
test the feasibility of and validate new outcome tools to assess SSI, wound management 70 
issues and patients’ wound symptom experiences. It is also exploring methods for avoiding 71 
performance bias and blinding outcome assessors by testing the feasibility of collecting 72 
wound photographs taken in theatre immediately after wound closure and, at 4-8 weeks after 73 
surgery, taken by participants themselves or their carers. Finally, it is identifying the main 74 
cost drivers for an economic evaluation of dressing types. Integrated qualitative research is 75 
exploring acceptability and reasons for non-adherence to allocation. Adults undergoing 76 
primary elective or unplanned abdominal general surgery or caesarean section are eligible. 77 
The main exclusion criteria are abdominal or other major surgery less than three months 78 
before the index operation or contraindication to dressing allocation. The trial is scheduled to 79 
recruit for nine months. The findings will be used to inform the design of a main trial.  80 
Discussion: This pilot trial is the first pragmatic study to randomize participants to no 81 
dressing or tissue-glue as a dressing versus a simple dressing. Early evidence from the on-82 
going pilot shows that recruitment is proceeding well and that the interventions are 83 
acceptable to participants. Combined with the qualitative findings, the findings will inform 84 
whether a main, large trial is feasible and, if so, how it should be designed. 85 
Trial registration: ISRCTN Registry number ISRCTN49328913, assigned on 20/10/2015.  86 
Keywords: Pilot study; feasibility study; randomised controlled trial; wound dressing; 87 
abdominal surgery, caesarean section, wound dressing, surgical site infection. 88 
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BACKGROUND 90 
It has been estimated that over 200 million operations are performed worldwide each year 91 
and about 4.5 million in England1. At the end of each procedure the skin edges of the wound 92 
are approximated using sutures or clips. Closing a surgical incision in this way creates what 93 
is called ‘a closed primary wound’. Following most surgery in adults, it is standard practice to 94 
cover closed primary wounds with a dressing. However, it is rare to apply dressings to 95 
closed primary wounds in children and in some specialist areas of adult surgery2. There are 96 
many different types of dressing available. They range from simple (basic) to complex 97 
(advanced) dressings; the latter may have absorbent or low adherence properties and some 98 
may interact with the wound to improve healing. The costs of different dressings vary too, 99 
from a few pence for basic wound contact dressings, to over £15 for advanced antimicrobial 100 
dressings3. 101 
 102 
Evidence about the effects of wound dressings on surgical wound healing in both adult and 103 
paediatric practice has been systematically reviewed4. The review found no evidence to 104 
suggest that covering surgical wounds with dressings reduces the risk of a surgical site 105 
infection (SSI) or that one wound dressing is more effective than another in reducing 106 
scarring, controlling pain, promoting patient acceptability or ease of dressing removal. 107 
However, the review authors also found that the available evidence was of poor quality; most 108 
studies were small and judged to be at high risk of bias. They acknowledged the logistical 109 
challenge of conducting a sufficiently large randomized controlled trial (RCT) to detect a 110 
small target difference in the frequency of SSIs with adequate power; a small target 111 
difference is likely to be required because of the high cost of a SSI5. The authors suggested 112 
that choices between wound dressing strategies (between dressing versus no dressing as 113 
well as between different dressings) could be based instead on their effects on dressing 114 
costs and patient acceptability issues, such as managing exudate and symptoms.  115 
 116 
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SSIs complicate up to 25% of surgical procedures6-8. Many SSIs resolve with simple 117 
antibiotic treatment but the more serious SSIs cause morbidity and pain, discomfort and 118 
inconvenience for patients. SSIs are costly for health services; the average cost of a SSI has 119 
been estimated to be at least £4,600 (lower 95% confidence limit)5.  After some operations, 120 
a SSI can threaten the principal outcome of the operation, the future health of the patient 121 
and possibly even their life, as well the principal objective of the operation9-13 . Therefore, 122 
every effort is made before, during and after surgery to minimise the risk of developing a 123 
SSI.  124 
 125 
A key challenge in designing a RCT to evaluate the effect of an intervention on SSI is 126 
choosing a method to assess SSI that is feasible for a large RCT and satisfies a wide range 127 
of stakeholders likely to have an interest in the findings. Definitions of a SSI have been 128 
described in another review14 which concluded that SSI definitions varied between 129 
surveillance programmes and hospitals and lacked good agreement. The authors 130 
recommended that future research should focus on developing a SSI measure with 131 
satisfactory psychometric properties; the measure should be formulated with the objective of 132 
detecting SSIs that are important to patients and health services, include post discharge 133 
surveillance and be suitable for application in everyday settings. 134 
 135 
The Bluebelle study has been funded by the National Institute for Health Research (NIHR) 136 
Health Technology Assessment (HTA) programme with the aim of establishing whether it is 137 
possible to carry out a large randomised controlled trial (RCT) to compare the effectiveness 138 
and cost-effectiveness of wound dressing types or no dressing on participant outcome15. It 139 
also aims to develop new and better outcome measures for the evaluation of wound 140 
dressings to use in a main trial. The Bluebelle study has two parts, Phase A and Phase B. 141 
Phase A comprised:  142 
 case studies in general abdominal and obstetric surgery to understand and explore the 143 
current use of dressings and views about not using dressings16;  144 
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 a survey of dressings currently used after primary wound closure17;  145 
 a review of the effectiveness and costs of dressings and contextual information (to 146 
update a Cochrane review4); 147 
 development and validation of questionnaire tools to assess SSI after discharge18 and 148 
practical wound management and participant symptom experience;  149 
 research to define metrics to measure the quality of wound closure and, through 150 
literature review, non-participant observations in theatres and interviews with surgeons;  151 
 several meetings with people who had had surgery during Phase A to consider key 152 
aspects of the study and participants’ involvement, including information from 153 
participants’ interviews.  154 
 155 
Phase B, a feasibility and external pilot trial19 informed by Phase A, is the subject of this 156 
protocol paper.  157 
 158 
AIMS AND OBJECTIVES 159 
The overall aim of Phase B of the Bluebelle Study is to carry out a feasibility and external 160 
pilot trial to establish whether it is possible to carry out a large definitive RCT. Based on 161 
findings from Phase A, the pilot trial is designed to investigate the practicability of an RCT to 162 
compare the effectiveness and cost-effectiveness of simple dressings, tissue adhesive used 163 
as a dressing (glue-as-a-dressing) and no dressing. The specific objectives are to: 164 
1. Establish the numbers of potentially eligible participants at different hospitals who can 165 
be approached about the trial, and the proportions confirmed as eligible, recruited and 166 
randomised.  167 
2. Pilot the randomisation process and attempt to address any issues before progressing 168 
to a main trial, including the risk of performance bias if allocation is revealed before 169 
wound closure.  170 
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3. Assess acceptability of the trial interventions and processes to participants and clinical 171 
staff using qualitative research methods, including methods to promote adherence. 172 
4. Assess adherence to dressing type allocation and the follow-up protocol and reasons for 173 
non-adherence. 174 
5. Assess the feasibility of collecting a range of secondary outcomes and resource use. 175 
6. Establish the validity and reliability of questionnaire tools for identifying SSI (wound 176 
healing questionnaire, WHQ), and describing wound management (WMQ) and a 177 
participant’s experiences of wound care (WEQ). 178 
7. Explore the feasibility of obtaining digital photographs of wounds taken by theatre 179 
personnel in theatre after wound closure and, at 4-8 weeks after surgery, taken by 180 
participants themselves or their carers. 181 
8. Explore aspects of the trial design and conduct with a patient and public involvement 182 
group to inform the conduct of Phase B and the design of a future main trial, following 183 
INVOLVE guidance20. 184 
 185 
STUDY DESIGN 186 
Phase B of the Bluebelle study is a pragmatic feasibility and pilot 3-group parallel RCT, 187 
using both quantitative and qualitative research methods (Figure 1). A SPIRIT Figure shows 188 
the different phases of the trial and data collection (Figure 2); a completed SPIRIT checklist 189 
is available as an additional file (additional file: 1 SPIRIT checklist). 190 
 191 
Trial registration, research approvals and research governance.  192 
The trial is registered with Current Controlled Trials; ISRCTN49328913 was assigned on 193 
20/10/2015. The sponsor for the trial is University Hospitals Bristol NHS Foundation Trust 194 
(research@uhbristol.nhs.uk) and has responsibility for monitoring trial conduct.  195 
 196 
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The funder and sponsor have no role in: study design; data collection, management or 197 
analysis; writing of reports; or any future decisions to submit reports for publication. The 198 
funder appointed an independent Study Steering Committee, overseeing both Phase A and 199 
Phase B. The funder and the REC agreed that a Data Monitoring and Safety Committee was 200 
unnecessary. Phase B was coordinated by the Clinical Trials and Evaluation Unit. A Study 201 
Executive Group monitors progress approximately monthly. 202 
 203 
Study population 204 
The setting for the research is secondary care, i.e. acute and maternity NHS hospitals. 205 
Patients aged 16 or older undergoing primary elective or unplanned open or laparoscopic 206 
abdominal general surgery (including, but not limited to, gastrectomy for benign or malignant 207 
disease, cholecystectomy, anti-reflux procedures, hepatic resection, small or large bowel 208 
resection for benign or malignant conditions, abdominal wall hernia surgery (inguinal, 209 
femoral, incisional, epigastric and para-umbilical)) or elective or unplanned obstetric surgery 210 
(caesarean section) are eligible. Patients undergoing simultaneous abdominal and chest 211 
surgery are eligible but only the abdominal wounds are allocated to one of the study 212 
interventions. At the time of recruitment, research nurses emphasise the need to attend a 213 
follow-up clinic 4-8 weeks after surgery and do not recruit patients who are unable to do so.  214 
 215 
Patients meeting the above criteria but with any of the following characteristics are ineligible:  216 
 abdominal or other major surgery less than three months before the index operation;  217 
 the surgeon intends to ‘close’ the wound with tissue adhesive (glue);  218 
 any contraindication to one of the dressing allocations including allergy to dressings;  219 
 surgery where no skin incision occurs;  220 
 lacking capacity to consent;  221 
 inability to complete patient-reported outcome questionnaires;  222 
 detained in the prison service.  223 
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All reasons for ineligibility are being recorded in the trial screening log, allowing the trial 224 
results to be reported in accordance with the CONSORT guidelines.  225 
 226 
Eligible patients are provided with written information (invitation letter and participant 227 
information leaflet (PIL, reviewed by the REC) and given as long as possible to consider the 228 
study before being approached for participation (usually more than 4 hours for elective 229 
surgery and usually more than 1 hour for unplanned surgery). Those having elective surgery 230 
may also be given these documents at a clinic visit before the operation, or be sent them in 231 
advance of admission. Research nurses or surgeons, who are responsible for approaching 232 
potential participants, do not request consent if a patient asks for longer thinking time and do 233 
not approach any patient who appears visibly distressed. 234 
 235 
Participants are also asked to consent to four optional aspects of the trial, designed to 236 
explore feasibility. The first relates to an interview about the acceptability of, and adherence 237 
to, the allocated dressing type (objectives 3 and 4). The second allows a local member of the 238 
research team to take a photograph of the wound(s) in the operating theatre, immediately 239 
after wound closure (objective 2). The third relates to the participant’s willingness to take a 240 
photograph of their wound(s) themselves 4-8 weeks after the operation and to send it to the 241 
research team (described to participants as a “wound selfie”, a term which was readily 242 
understood; objective 7). The fourth covers consent for a skin transfer to be applied after the 243 
operation to remind staff that the participant is in the study. 244 
 245 
Surgery is carried out according to local protocols for the operation. Apposition of wound 246 
edges and the method of closure of the skin is at the discretion of the surgeon and may 247 
include sutures, clips, wound closure strips or combinations of these wound closure 248 
methods.  249 
 250 
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Randomisation  251 
Participants are randomised to one of three dressing groups. Participants are also 252 
randomised to disclosure of the dressing group allocation to the surgeon before wound 253 
closure or after wound closure. These two randomisations create six groups (Figure 1). Both 254 
randomisations are in blocks of varying size and stratified by hospital Trust and speciality 255 
(abdominal surgery/obstetric surgery). The sequences of random allocations were generated 256 
by computer in advance of starting to recruit. Local research team members access a 257 
participant’s allocation via the internet. The allocation is concealed until a participant’s 258 
eligibility and consent have been documented and information to identify the participant 259 
uniquely has been entered. 260 
 261 
At the beginning of the operation, a member of the local research team (trainee or consultant 262 
surgeon/research midwife or nurse) logs on to the randomisation website (within the study 263 
database) using a secure password-protected computer system and enters the information 264 
needed to proceed to randomise the participant. Depending on the randomisation result, the 265 
dressing group allocation is disclosed immediately or the user is advised to log back into the 266 
website after the wound has been closed and enter the time of wound closure, after which 267 
the allocation is disclosed.  268 
 269 
The second randomisation, the disclosure of allocation before or after wound closure, relates 270 
to objective 2. During preliminary discussions about the trial, the trials unit proposed that 271 
randomisation should occur after wound closure, to prevent surgeons closing the wound in 272 
different ways depending on the allocation, but surgeons considered that this would be 273 
problematic. The second randomisation allows the trial to test the feasibility of randomising 274 
after wound closure to be tested. Moreover, if photographs of the closed wound can be 275 
obtained in the operating theatre and subsequently assessed for the quality of wound 276 
closure, the effect of timing of randomisation on wound closure can be investigated. 277 
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 278 
Blinding  279 
It is not possible to blind surgeons, participants or staff caring for participants to the dressing 280 
allocation. However, we plan to blind research staff assessing outcomes 4-8 weeks after 281 
randomisation and methods to achieve blinding are being piloted to test their feasibility and 282 
acceptability for the main trial. These include requiring the reference SSI assessment and 283 
the wound healing questionnaire to be completed by health care professionals who have not 284 
been involved in a participant’s care during the index admission. (The study also requires 285 
these assessments to be done by different people, in order to validate the wound healing 286 
questionnaire.) The success of blinding among assessors of SSI 4-8 weeks after 287 
randomisation (health care professionals completing the reference SSI assessment or the 288 
WHQ) is being assessed by asking them which study group they think that the participant is 289 
allocated to. 290 
 291 
If the occurrence of an SSI can be assessed from a photograph after a dressing has been 292 
removed, the assessment of the photograph could be blinded. For this reason, the trial is 293 
testing the feasibility of participants submitting wound selfies securely to the trial database.  294 
 295 
Integrated qualitative research 296 
A qualitative study is integrated into the pilot study, to provide insights into the feasibility and 297 
potential design of a main trial. The study uses semi-structured interviews to explore 298 
participants’ experience/acceptability of participating in the trial, staff experiences of 299 
delivering trial processes/follow-up, and participant/staff perspectives on reasons for protocol 300 
deviations. All patients who agree to participate in the pilot RCT are also asked if they are 301 
willing for their contact details to be shared with the qualitative research team. Patients who 302 
provide written consent to be contacted form the sampling frame for the interviews. Potential 303 
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interviewees are purposefully sampled from this frame, with the intention of including a range 304 
of individuals based on the following criteria: 305 
 Surgical speciality (upper GI, lower GI, or obstetric) 306 
 Surgical approach (laparoscopic or open procedures) 307 
 Nature of hospital admission (elective or unplanned) 308 
 Bluebelle study allocation (simple dressing, ‘no dressing’, or ‘glue-as-a-dressing’) 309 
Healthcare professionals considered to be ‘key informants’ are purposefully selected for 310 
potential interview. ‘Key informants’ are defined as any individuals with responsibility for 311 
caring for Bluebelle participants or delivering aspects of the pilot RCT (e.g. recruitment, 312 
randomisation, follow-up). 313 
 314 
Topic guides have been developed in the light of earlier findings (Phase A 16), and are being 315 
iteratively developed in light of emerging findings as data collection and analysis proceeds. 316 
Interviews will be conducted face-to-face or via telephone by members of the qualitative 317 
research team (LR and CM). 318 
 319 
Interviews with participants explore the acceptability of trial interventions and trial processes, 320 
reasons for withdrawal (if appropriate), and sources of non-adherence (i.e. instigated by staff 321 
or participants themselves).  Participants may be interviewed at two time points; soon after 322 
surgery (within a week); and around their 4-8 week follow-up visit / assessment.  A major 323 
finding from the qualitative research during Phase A was that clinical staff anticipated 324 
challenges in delivering the trial in practice. Therefore, interviews with health care 325 
professionals are exploring their experiences of implementing study protocols in practice and 326 
perceived reasons for non-adherence.  327 
 328 
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Trial interventions  329 
Participants are randomised to one of three standard dressing groups: simple dressing (the 330 
comparator, believed to represent usual care17), no dressing or glue-as-a-dressing.  331 
 332 
A simple dressing is defined as a covering (opaque or transparent) that is applied directly to 333 
an already closed wound, over the entirety of the wound, adherent around its entire 334 
perimeter or surface in contact with the skin. It may or may not have absorbent properties. 335 
Box 1 shows examples of commonly available simple dressings. Hospital Trusts may have 336 
other types available and use the dressing that represents usual care. 337 
 338 
Tissue adhesives are topical skin adhesives. In this trial, they are applied according to the 339 
manufacturers’ instructions and must be applied only to the surface of an already closed 340 
primary wound, acting as a dressing (not to close the wound, i.e. below skin level). A recent 341 
survey found that glue-as-a-dressing is a dressing strategy that is often used by general 342 
surgeons17 but it is considered here as one of the two interventions, compared to a simple 343 
dressing (the comparator). Box 2 shows examples of commonly available tissue adhesives 344 
that can be used.  345 
 346 
In the no dressing group, at the end of the operation when the skin has been closed, no 347 
simple dressing or tissue adhesive is applied to the wound. The wound is therefore left 348 
exposed without a covering as is the standard approach for many types of surgery, 349 
particularly in children15. 350 
 351 
The following aspects of wound care apply to all interventions: 352 
 A participant’s wounds should be dressed according to the participant’s treatment 353 
allocation throughout their hospital stay. 354 
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 When a participant has more than one wound (e.g. multiple port sites for laparoscopic 355 
surgery), all the eligible wounds are dressed according to the treatment allocation. 356 
 Re-dressing of a wound in hospital may be needed if there is slow discharge or on-going 357 
seepage of fluid ("ooze") from the wound in the first 24 hours or if a SSI occurs (i.e. after 358 
the outcome of interest has been ascertained). For the former, a simple gauze swab can 359 
be applied to the area that is oozing; this is allowed in the no dressing group as well as 360 
the other groups. The swab should be taped in place temporarily and not around its entire 361 
perimeter. Examples of swabs that can be used are listed in Box 3. If oozing continues, 362 
the clinical team may apply any dressing to the wound (or re-suture it if necessary); where 363 
this represents deviation from the allocated dressing, the action is documented in the 364 
case report forms (CRFs).  365 
 Co-interventions that may influence SSI rates (e.g. the use of prophylactic antibiotics and 366 
other aspects of pre-, peri- or post-operative care) will be allowed at the discretion of the 367 
team and hospital looking after the participants. Their distribution by allocated group is 368 
being monitored, in view of the risk of bias due to differential implementation of co-369 
interventions when the usual care team is not blinded to the allocated dressing. This 370 
information will inform decisions about the need to standardise care when designing the 371 
main trial. 372 
 To encourage adherence to treatment allocation, colour-coded skin transfers showing the 373 
study logo and the dressing allocation are provided. These are applied on the 374 
participant’s skin, near to the surgical wound(s), as a reminder to health care 375 
professionals looking after the patient about the patient’s participation in the trial and the 376 
allocated dressing strategy (Figure 3). The skin transfer disappears over time and is not 377 
visible by the time of the 4-8 week assessment. 378 
 379 
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Study centres and surgeons 381 
Four NHS hospital Trusts are taking part, one of which is recruiting participants having either 382 
abdominal surgery or caesarean section. (Three Trusts had agreed to take part at the outset 383 
and a fourth Trust, recruiting patients having abdominal surgery, joined in month 6.) All 384 
general surgical teams carry out a wide range of operations. The participating obstetric unit 385 
carries out about 1,800 caesarean sections each year. Since the operations are all being 386 
carried out as part of the usual care of participants, there are no restrictions on operating 387 
personnel or ward care. 388 
 389 
Primary outcome 390 
The primary outcome is successful screening of a participant, determination of the 391 
participant’s eligibility and consent to be randomised in the pilot trial, at the time of 392 
randomisation. This information, together with the denominator describing the total number 393 
of participants approached, will establish whether recruitment into the main trial is possible. 394 
 395 
Secondary outcomes 396 
These will include: 397 
(a) Adherence to disclosure of dressing category allocation at the designated time. 398 
(b) Adherence to the allocated dressing type by the usual care team during the index 399 
hospital admission and, if applicable, reason for non-adherence. 400 
(c) Quality and completeness of the data for different outcomes anticipated to be measured 401 
in the main trial (see below; assessed at different times), including component 402 
assessments contributing to an overall judgement about the occurrence of a SSI. 403 
(d) Adherence to the follow-up schedule. 404 
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(e) Documentation of co-interventions (e.g. details of hair removal, use of skin cleansing 405 
agents, type of wound closure methods, prescription of prophylactic antibiotics) and 406 
classification of surgery as ‘clean’, ‘contaminated’ or ‘dirty’ at the time of the operation. 407 
(f) Completion of the reference SSI assessment at 4-8 weeks by a blinded observer.  408 
(g) Completion of a wound healing questionnaire (WHQ18 at 4-8 weeks by a blinded 409 
observer and by the participant. 410 
(h) Completion of a wound management questionnaire (WMQ; developed during Phase A) 411 
up to 4 days after randomisation by an observer or the participant (if discharged early, 412 
e.g. day case surgery)  413 
(i) Completion of a wound experience questionnaire (WEQ; developed during Phase A) up 414 
to 4 days after randomisation by the participant. 415 
(j) Assessment of wounds from digital photographs at 4-8 weeks, if submitted. 416 
 417 
Bluebelle is a feasibility study and some of these secondary outcomes were developed in 418 
Phase A and are being piloted in Phase B. Therefore, detailed scoring methods are not 419 
currently available. We will report the questionnaire response rates, the number of fully 420 
completed questionnaires and rates of missing items in this pilot RCT as part of the 421 
evaluation of the acceptability of the new questionnaires to patients. The data from the pilot 422 
trial are also being used to validate some of the questionnaires.  423 
 424 
Anticipated outcomes in a subsequent main trial 425 
The following outcomes are expected to be assessed in a main trial; the ability to collect 426 
these outcomes is, therefore, a key focus of the pilot trial: 427 
(a) Occurrence of a SSI up to 4-8 weeks after randomisation (primary). 428 
(b) Wound management questionnaire. 429 
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(c) Patient reported outcomes: wound experience questionnaire, documenting symptoms 430 
and experiences of the wound and dressings, and generic health status, assessed by 431 
the EQ-5D-5L21. 432 
(d) Wound complications arising up to 4-8 weeks after randomisation. 433 
(e) Resource use up to 4-8 weeks, including length of postoperative hospital stay, rates of 434 
re-admission and duration. 435 
 436 
Trial procedures and data collection up to 4 days after randomisation 437 
The schedule of data collection is described in the SPIRIT Figure (Figure 2). 438 
 439 
Surgery and closure of wounds takes place as per usual practice. A member of theatre 440 
personnel, or research team, records: i) the time taken to close the wound, ii) use of 441 
laparoscopic or open surgical methods, iii) the method of wound closure. A member of 442 
theatre personnel or research team may also take one or more digital photographs of the 443 
wound(s). If randomised to disclosure of allocation after wound closure, the time of 444 
completing wound closure must be entered into the database to obtain the allocation. A 445 
range of methods are being used to promote adherence to the randomised dressing 446 
allocations in hospital, adapted to the circumstances of participating hospitals. These include 447 
simple labels, to be attached to medical notes or placed by the bedside, as well as skin 448 
transfers (Figure 3). 449 
 450 
Up to 4 days after surgery, after any early wound care that is required, a health care 451 
professional completes the WMQ. This questionnaire captures information about aspects of 452 
the participant’s wound management. If discharged early, e.g. after day case surgery or the 453 
day after surgery, the research team gives the participant the WMQ to complete by day 4 454 
and send back to the trials unit in a pre-paid envelope. 455 
 456 
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The local research team gives each participant the WEQ to complete up to 4 days after 457 
surgery. For participants who are in hospital at this time, the WEQ is collected by the 458 
research team. If discharged early, e.g. after day case surgery or the day after surgery, the 459 
participant completes the WEQ at home by day 4 and sends it back to the trials unit in a pre-460 
paid envelope. 461 
 462 
  463 
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Data collection up to 4-8 weeks after randomisation  464 
Local research teams give each participant a copy of the EQ-5D-5L and a pre-paid reply 465 
envelope to take home and are instructed to complete and return it if a wound becomes 466 
infected or problematic. The reason for asking for the EQ-5D-5L to be completed is to try to 467 
document the peak impact of a wound problem on health status to inform a future health 468 
economic evaluation. 469 
 470 
Several follow-up assessments are required 4-8 weeks after randomisation. First, the 471 
participant needs to complete a copy of the EQ-5D-5L and the WHQ; these questionnaires 472 
can be given to participants at discharge from hospital or posted shortly before they fall due. 473 
Around this time, participants who have agreed to send a photograph may also be sent an 474 
email or text message including a web-link that allows them to upload a photograph 475 
securely. Then, a blinded health professional needs to complete the WHQ; this can be done 476 
face-to-face, typically at the same clinic attendance but before the reference SSI 477 
assessment, or administered by telephone. Finally, the face-to-face reference SSI 478 
assessment is completed by a blinded health professional, who must be different to the one 479 
completing the WHQ; this assessment includes eliciting information about potential wound-480 
related complications. Whenever possible, the face-to-face clinic visit is arranged to coincide 481 
with a usual care clinic appointment. When this is not possible, travel expenses are offered 482 
to the participant. For women who have had a caesarean section, the WHQ questionnaire is 483 
administered by telephone and research midwives then carry out the reference SSI 484 
assessment at a home visit. 485 
 486 
To promote retention, reminders are sent out to participants who fail to return postal 487 
questionnaires promptly. Participants who fail to attend for the face-to-face SSI assessment 488 
are offered further appointments. 489 
 490 
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Source data  491 
The operation and medical notes, and other information held electronically on hospital 492 
information systems, provide source data for participant demographic and baseline 493 
information, operation details and post-operative morbidity. The completed participant 494 
questionnaires and observer-reported assessments of SSI and wound management are the 495 
primary data source for these measures. The data source for secondary and adverse 496 
outcomes will be the participant’s medical notes. Wound photographs are the primary data 497 
source for this outcome. 498 
 499 
Staff at participating centres record data on paper CRFs, then use a password-protected 500 
web server application to transcribe the data into a custom-designed database, located on a 501 
secure NHS server. The database has validation on data fields.  502 
 503 
Assessment and analysis of resource use 504 
The pilot trial will assess the feasibility of collecting health care resource use data from the 505 
CRFs completed during the admission and at the 4-8 week follow-up. Relevant resource use 506 
is expected to fall under the following categories: 507 
(a) The wound dressing itself; 508 
(b) Post-operative resources expended in the hospital setting; 509 
(c) SSI-related care; 510 
(d) Post-discharge resources expended in primary care. 511 
 512 
The analysis will involve an assessment of the quality and completeness of the data for each 513 
data item, for example data on type of wound dressing and frequency of use, and other data 514 
on health care services provided in the hospital setting (i.e. post-randomisation hospital stay 515 
and follow-up outpatient appointments to assess wound healing). It will also start to consider 516 
the main drivers of cost, so that these can be accurately collected within the main trial. 517 
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 518 
Unit cost information associated with different types of care will be collected or estimated in 519 
preparation for the main trial and to ensure that these costs are available or can be 520 
generated. Particular attention will be paid to understanding the costs associated with SSIs 521 
as preliminary modelling suggests that these costs, rather than the costs of dressings, are 522 
likely to be the main driver of any cost differences between the arms of the trial. Preference-523 
based quality-of-life estimates for the entire cohort will be derived by translating patients’ 524 
responses to the EQ-5D-5L over the 4-8 weeks after randomisation into utility values using 525 
the latest value set for England22.  526 
 527 
Trial duration 528 
The trial is timetabled to take up to 11 months, randomising the target number of 330 529 
participants in 9 months and then following up the last participants for 4-8 weeks.  530 
 531 
Sample size  532 
A pilot study of 920 eligible participants, will allow a recruitment rate of 36% (corresponding 533 
to the target number randomised of 330) to be estimated with a 95% confidence interval (CI) 534 
of 32% to 39%, and a recruitment rate of 60% with 95% CI of 56% to 64%. For the simple 535 
dressings group, we anticipate an adherence rate of 90%. Assuming a 36% recruitment rate 536 
and 110 randomised participants per group, a 90% adherence rate will be estimated with a 537 
95% CI of 82 to 95%. We have no information on which to base any estimate of adherence 538 
in the no dressing and glue-as-a-dressing groups. However, if adherence were less than 539 
70% in either group we would conclude that randomisation to the group in question in the 540 
main trial would not be feasible. 541 
 542 
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Statistical analyses 543 
Summary descriptive statistics to inform plans for the main trial will be reported including: 544 
(a) the number of potentially eligible participants per month per centre;  545 
(b) the percentage of these potential participants confirmed as eligible;  546 
(c) the percentage of participants agreeing to be randomly allocated to dressing type in the 547 
pilot RCT;  548 
(d) the percentage of randomised participants receiving the allocated treatment and 549 
completing outcome measurements at the 4-8 week assessment;  550 
(e) rate of, and reasons for, non-adherence to allocation at both a wound and participant 551 
level; 552 
(f) mean number of wounds per participant; 553 
(g) mean (or median if skewed) time from wound closure to randomisation; 554 
(h) mean (or median if skewed) time to complete randomisation process;  555 
(i) completeness of data items and reasons for missing data; 556 
(j) rate of unblinding of outcome assessors and reasons for unblinding; 557 
(k) secondary outcome measures relating to wound closure will be compared between 558 
groups, if the data allow. 559 
 560 
Only the statisticians (CAR and RAH) will have access to the data. The analysis population 561 
will include all randomized participants. Results will be described by centre and by specialty 562 
as well as overall. If the data allow, subgroup analyses of the secondary outcome measures 563 
relating to wound closure will estimate the interaction of timing of randomisation by dressing 564 
group. 565 
 566 
The primary analysis will take place when follow-up is complete for all recruited participants. 567 
During the pilot trial, we are monitoring recruitment and adherence periodically. The study 568 
steering committee will review safety data. In any interim reports, for example about 569 
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withdrawals after randomization, the data will be presented by group with uninformative 570 
labels to keep the allocation masked. 571 
 572 
Dissemination 573 
The results of the pilot trial will be reported in peer-reviewed journals, in a report to the 574 
funder and as a lay summary to participants. We will apply authorship criteria established by 575 
the International Committee of Medical Journal Editors. 576 
 577 
Changes to the protocol since first approved 578 
This paper describes protocol version 5 (21 Oct 2016). Two substantial amendments have 579 
been approved.  580 
 581 
Version 2 was the first approved protocol. The first amendment (from v2 to v3) was 582 
approved (08/12/2015) before starting to recruit. Due to the short duration of the pilot trial, 583 
REC approval was obtained for a design as conceived at the outset for the study, before 584 
Phase A was completed. The first amendment described revisions to this protocol that were 585 
required as a result of the findings from Phase A16. The funding application for the study 586 
always envisaged that Phase B would be informed by Phase A. The time constraints for the 587 
overall study (both Phase A and Phase B), combined with the time needed to obtain REC 588 
approval, made it inevitable that an amendment would be required after Phase A ended. 589 
This amendment included: changing the trial population to include patients having unplanned 590 
operations; substituting the intervention of a complex dressing with glue-as-a-dressing; 591 
addition of the WMQ and WEQ as secondary outcomes. 592 
 593 
The need for a second amendment (v3 to v4, then to v5 to accommodate a change 594 
requested by the REC) arose from initial difficulties in recruiting patients having unplanned 595 
surgery and obtaining patient-reported follow-up questionnaires. This amendment (approved 596 
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06/09/2016) substituted a 4-hour period between giving the PIL to a potential participant and 597 
requesting consent by the statement “as long as possible”, qualifying this as “usually more 598 
than 4 hours for elective surgery and usually more than 1 hour for unplanned surgery”. We 599 
justified this on the basis of feedback from trainee surgeons and research nurses that 600 
potential participants did not require ‘thinking time’ in order to decide whether to take part. 601 
We also revised the protocol to allow the 4-8 week WHQ to be administered over the 602 
telephone by a health professional, as well as face-to-face. We applied for the trial to be 603 
adopted by the Health Research Authority shortly after submitting the amendment, in order 604 
to obtain approval for another NHS Trust to recruit patients having abdominal surgery. 605 
 606 
DISCUSSION 607 
The short duration of the pilot trial, constrained by the length of the overall research contract, 608 
has been a challenge. The design of pilot trial depended on the findings of Phase A and the 609 
design was finalised shortly before starting to recruit. Despite this, final preparation and the 610 
two site initiation visits took place in just 10 weeks, after notification that the first amendment 611 
had been approved. Development of the trial database was split into two releases, one to 612 
allow recruitment and randomisation, and the second for entry of data captured on paper 613 
CRFs. 614 
 615 
Status of the pilot trial 616 
Recruitment is ongoing and is on target to achieve at the pre-specified sample size in the 617 
scheduled time. The interventions appear to be acceptable to potential participants and over 618 
50% of those who have been approached to take part have given written consent. After 619 
some initial deviations, adherence has also been good; in particular, members of local 620 
research teams have reported that the skin transfers are an acceptable and effective way to 621 
promote adherence. Qualitative interviews have also indicated that the interventions are 622 
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acceptable and that there have been few issues with adherence. Further details about the 623 
feasibility outcomes will be reported fully in due course. 624 
 625 
LIST OF ABBREVIATIONS 626 
CI Confidence interval 
CONSORT Consolidated standards of reporting trials 
CRF Case report form 
EQ-5D-5L 5-level EuroQol health status questionnaire 
HTA Health Technology Assessment 
NHS National Health Service 
NIHR National Institute for Health Research 
PIL Patient information leaflet 
RCT Randomised controlled trial 
REC Research Ethics Committee 
SMG Study Management Group 
SSC Study Steering Committee 
SSI Surgical site infection 
UK United Kingdom 
WEQ Wound experience questionnaire 
WHQ Wound healing questionnaire 
WMQ Wound management questionnaire 
 627 
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 805 
Table and Figure legends 806 
 807 
Figure 1 Trial schema 808 
Schema showing the pathway for patients recruited into the Bluebelle Phase B external pilot 809 
trial, including the double randomisation. 810 
 811 
Figure 2 SPIRIT figure  812 
The figure shows the phases of the trial and data collection time points. 813 
 814 
Figure 3 Skin transfers 815 
Image shows a skin transfer applied near to the wound(s) to promote adherence to the 816 
randomised dressing allocation. 817 
 818 
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Box 1 Examples of commonly used simple dressings 
 
Bioclusive® 
C-View® 
Hydrofilm® 
Opsite® 
Mepore® 
Tegaderm® 
 
 
  
 
 
 
Table Click here to download Table Box 1.docx 
 Box 2 Examples of commonly used types of tissue adhesive  
 
Dermabond ProPen® 
Epiglu® 
Histoacryl® 
LiquiBand®  
Table Click here to download Table Box 2.docx 
 Box 3 Example of swabs that can be to manage wound exudate  
 
Gauze Swabs 
Filmated Gauze Swabs 
Non-woven Fabric Swabs 
Filmated Non-woven Fabric Swabs 
Knitted viscose 
Paraffin gauze dressings  
Table Click here to download Table Box 3.docx 
 Randomise prior to start of surgery 
Dressing allocation provided to 
surgeon  
n = 165 
Dressing allocation not provided to 
surgeon 
n = 165 
Wound closed 
Simple dressing            
n = 55 
Glue-as-a-dressing    
n = 55         
No dressing 
n = 55 
Wound closed 
Simple dressing            
n = 55 
Glue-as-a-dressing    
n = 55 
No dressing 
n = 55  
Dressing allocation provided to 
surgeon 
n = 165 
Figure Click here to download Figure Figure 1 Randomisation Schema.pdf 
1 
OR 
Figure 2: SPIRIT figure 
 STUDY PERIOD 
 Enrolment Allocation Post-allocation Close-out 
 In hospital Post discharge 
 Pre-
randomisation 
Before surgery After wound 
closure 
Up to 4 days 
after surgery 
Any time if wound 
problem  
Day 15 post- 
surgery 
4-8 weeks 
post- surgery 
TIMEPOINT (days)  0 0 +4 1-56 +15 28-56 
ENROLMENT:        
Eligibility screen X       
Informed consent X       
Randomisation to dressing 
allocation 
 X      
Randomisation to time of 
disclosure of dressing allocation 
 X      
Disclosure of dressing allocation   X X     
INTERVENTIONS:        
Simple dressing  X      
Glue-as-a-dressing  X      
No dressing  X      
ASSESSMENTS:        
Demographics X       
EQ-5D-5L X    X X X 
Adherence to allocation  X X X   X 
Type(s) of wound dressing and 
frequency of use 
  X X   X 
Resource use   X X   X 
WMQ (observer or participant)    X    
WEQ (participant)    X    
WHQ (participant)       X 
WHQ (observer)       X 
Wound photograph by 
participant (optional) 
      X (for a 
subgroup) 
Reference SSI assessment       X 
Figure Click here to download Figure Figre 2 SPIRIT Figure v1.0.docx 
2 
SSI-specific resource use       X 
QUALITATIVE:        
Qualitative interview 
(telephone or face-to-face) 
(optional) 
X   X   X 
Audio-recording of consultation 
about study participation 
(optional) 
X       
WMQ – wound management questionnaire; WEQ – wound experience questionnaire; WHQ – wound healing questionnaire (to ascertain surgical site 
infection). 
 
  
Figure Click here to download Figure Figure 3 Skin transfer.pdf 
